Clinical Trials Logo

Citation(s)

A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)

Details for clinical trial NCT03364036